Biotech Values

[floblu14]

MOMENTA PHARMACEUTICALS - ON DEC. 19, 2013, BAXTER TERMINATED ITS OPTION TO LICENSE M511 UNDER BAXTER AGREEMENT FOLLOWING AN INTERNAL PORTFOLIO REVIEW
Dec 20 (Reuters) - Momenta Pharmaceuticals Inc <MNTA.O>:

* On December 19, 2013, Baxter terminated its option to license m511 under

Baxter agreement following an internal portfolio review

* Co, Baxter are continuing to collaborate on m923 and m834 and evaluate

additional products for development

* Company will continue to develop m511 as part of its biosimilar business.

* Says co may also consent, at its option, to allow Baxter to name a

replacement product for m511, if Baxter requests

* Now targeting aggregate milestones of $19 million associated with m923 and

m834 in 2014 - SEC filing

* Baxter has right, until February 2015, to select up to three additional

biosimilars to be included in collaboration

Source text for Eikon (http://link.reuters.com/wuc65v)